Exploring future spinal cord injury therapies
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
List view / Grid view
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
A molecule has been shown to increase dopamine levels in the brains of mice, offering hope for stopping the progression of Parkinson’s.
A microRNA inhibitor has been identified which reduced the sizes of aggressive CNS tumours and improved survival in mice.
Researchers have polymerised oestrogen using a new approach and found it is effective at protecting and regenerating nervous system cells in vitro.
Researchers have identified a protein on the surface of cells that cause MS and have used antibodies as an effective treatment for the condition in mice.
Chronic inflammatory processes in ageing brains lead to lymphoma cells that have entered the brain tissue being retained.
Structural and functional study of the nervous system, also known as Neuroscience, is one of the scientific fields that has always crystallized the hopes and fantasy of humankind - not only interms of disease understanding and treatment but also in terms of capacity improvement.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
A team has developed a technique for identifying pluripotent stem cells that could help research on transplantation medicine.
The advent of in vitro culturing of neural cells has been central to driving our understanding of the nervous system.
A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled.
A study reveals a complex interplay of two different growth factors in the rapid and long-lasting antidepressant effects of ketamine...
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer's disease...
Genetic variants which prevent a neurotransmitter receptor from working properly have been implicated in the development of schizophrenia...
SB Drug Discovery shows the validation of fluorescence and automated electrophysiology assays designed to assess agonists, antagonists and allosteric modulators of these receptors, culminating in a high-throughput electrophysiology assay suited to assessing multiple GABAA receptor subtypes on a single assay plate.